Sylentis

Executive Summary

Sylentis is a Spanish biopharmaceutical company, a subsidiary of PharmaMar, specializing in RNA interference (RNAi) therapeutics for ocular diseases. Founded in 2006 and headquartered in Madrid, the company leverages its proprietary SirFinder™ AI platform to rationally design siRNA compounds that silence disease-causing genes. Sylentis aims to improve and preserve vision by developing innovative treatments for conditions such as glaucoma, diabetic retinopathy, and age-related macular degeneration. With a strong foundation in RNAi biology and computational design, the company is positioned to address significant unmet needs in ophthalmology. Backed by the resources and expertise of PharmaMar, Sylentis is advancing its pipeline toward clinical development, focusing on targets validated by genetic evidence. While still in preclinical stages, the company's technology platform and strategic focus on ocular diseases offer a differentiated approach in the competitive RNAi landscape.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1 Clinical Trial for Lead siRNA Candidate70% success
• Q2 2026Presentation of Preclinical Data at Major Ophthalmology Conference (e.g., ARVO)80% success
• H2 2026Potential Licensing or Collaboration Agreement for Ocular RNAi Platform50% success